{"entity":{"id":"personalis","kind":"company","name":"Personalis (Tempus)","aka":[],"tldr":"Maker of the ultra-sensitive NeXT Personal MRD test, being acquired by Tempus AI for about $1.5B (announced July 2026).","summary":"Personalis, based in Fremont, California, and listed as PSNL, makes the ultra-sensitive NeXT Personal test for measurable residual disease and is being acquired by Tempus AI for about 1.5 billion dollars, announced in July 2026. NeXT Personal is a tumour-informed whole-genome MRD assay whose clinical volumes grew 33 percent quarter over quarter to 10,384 tests in the second quarter of 2026, and Tempus agreed to pay 16.25 dollars per share in stock, with closing expected in late 2026 or early 2027. OnCo links it to MRD testing, liquid biopsy and whole-genome sequencing, to the MRD term, to Tempus, and to the idea of pushing residual disease detection a hundredfold deeper with whole-genome methods. Whether deeper detection changes treatment decisions or only finds relapse sooner is the open question. Tempus has its own page.","asOf":"2026-09-04","links":[{"label":"Tempus acquisition","url":"https://investors.tempus.com/news-releases/news-release-details/tempus-acquire-personalis-more-tightly-integrating-molecular"}],"tags":[],"related":[],"cancers":[],"sections":["diagnostics"],"technologies":["mrd-testing","liquid-biopsy","wes-wgs","cgp"],"targets":[],"drugs":[],"companies":["tempus"],"institutions":[],"pathways":[],"terms":["mrd"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Fremont, CA","country":"US","companyType":"diagnostics","website":"https://www.personalis.com","ticker":"PSNL","investors":[],"funding":[]},"route":"/companies/personalis/","neighbours":{"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"company":[{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/"}],"term":[{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"idea":[{"id":"idea-bio2-whole-genome-mrd-depth","kind":"idea","name":"Push residual disease detection a hundredfold deeper with whole-genome methods","route":"/ideas/idea-bio2-whole-genome-mrd-depth/"}]}}